Follistatin 344 Made in USA — Third-Party Verified
Follistatin 344 is an autocrine glycoprotein widely investigated in preclinical models for its binding affinity to activin A and myostatin. PX1 Research supplies domestically synthesized Follistatin 344 validated by lot-specific HPLC/MS mass spectrometry, ISO 17025 third-party analytical verification, and stringent endotoxin screening to support reproducible laboratory investigations.
Quick answer
Follistatin 344 is an autocrine glycoprotein widely investigated in preclinical models for its binding affinity to activin A and myostatin. PX1 Research supplies domestically synthesized Follistatin 344 validated by lot-specific HPLC/MS mass spectrometry, ISO 17025 third-party analytical verification, and stringent endotoxin screening to support reproducible laboratory investigations.
Key takeaways
- Follistatin (FST) is a naturally occurring monomeric glycoprotein expressed in almost all vascularized tissues.
- Sourcing laboratory reagents requires stringent control over synthetic pipelines.
- Preclinical investigation into Follistatin 344 centers largely on its role as a high-affinity antagonist to specific members of the TGF-β superfamily, primarily Activin A and Myostatin (Growth Differentiation Factor 8, or GDF-8).
- To guarantee sequence fidelity and analytical purity, every single lot of Follistatin 344 synthesized for PX1 Research undergoes rigorous testing at an independent, ISO 17025-accredited analytical laboratory.
Molecular Profile and Structural Architecture of Follistatin 344
Follistatin (FST) is a naturally occurring monomeric glycoprotein expressed in almost all vascularized tissues. The precursor gene encodes a 344-amino acid peptide, often designated as Follistatin 344 (FST-344). In physiological systems, alternative splicing and carboxyl-terminal proteolytic processing yield distinct isoforms, including the membrane-bound FST-315 and the circulating core form, FST-288. Within experimental frameworks, follistatin 344 made in usa serves as a baseline full-length peptide precursor utilized to examine autocrine and paracrine signaling cascades.
Structurally, the polypeptide contains an N-terminal domain followed by three conserved follistatin domains (FS1, FS2, and FS3), each rich in cysteine residues that form crucial intra-chain disulfide bonds. These cysteine knots confer significant biochemical stability and dictate the tertiary structure necessary for receptor-ligand interaction. Laboratory assays indicate that the primary structural motif of FST-344 allows it to interact directly with transforming growth factor-beta (TGF-β) superfamily ligands, effectively masking their active binding sites and preventing downstream receptor complex activation.
The Strategic Importance of USA-Synthesized Research Peptides
Sourcing laboratory reagents requires stringent control over synthetic pipelines. Peptides produced outside highly regulated domestic frameworks frequently present batch-to-batch variability, residual counter-ion contamination, or uncharacterized sequence truncated impurities. Securing high-purity research peptides synthesized within the United States mitigates these structural risks, ensuring that experimental variables remain tightly controlled across long-term study protocols.
PX1 Research enforces complete domestic production protocols for its catalog. Synthetic sequence assembly, cleavage, purification, and lyophilization occur exclusively within cGMP-compliant facilities located in North America. This domestic manufacturing footprint guarantees traceable chains of custody, strict adherence to environmental controls, and immediate compliance with rigorous quality specifications required by academic, biotechnology, and institutional research facilities.
Mechanisms of Action: Activin Neutralization and Myostatin Pathway Modulation
Preclinical investigation into Follistatin 344 centers largely on its role as a high-affinity antagonist to specific members of the TGF-β superfamily, primarily Activin A and Myostatin (Growth Differentiation Factor 8, or GDF-8). In vitro binding kinetics demonstrate that Follistatin 344 binds Activin A with nanomolar affinity, forming an irreversible, biologically inactive complex that prevents Activin from engaging its cell-surface serine/threonine kinase receptors (ActRIIA and ActRIIB).
By neutralizing circulating and tissue-specific Activin A and GDF-8, Follistatin 344 blocks the activation of intracellular Smad2 and Smad3 transcription factor pathways. In rodent models of muscle wasting and fibrosis, inhibition of Smad2/3 signaling correlates with a shift toward hypertrophic signaling via the Akt/mTOR network. Investigators utilizing follistatin 344 made in usa examine these biochemical pathways to evaluate cell-cycle regulation, satellite cell activation, and tissue remodeling mechanisms without the confounding effects of low-purity reagent artifacts.
ISO 17025 Third-Party Analytical Verification and COA Standards
To guarantee sequence fidelity and analytical purity, every single lot of Follistatin 344 synthesized for PX1 Research undergoes rigorous testing at an independent, ISO 17025-accredited analytical laboratory. Purity is confirmed using High-Performance Liquid Chromatography (HPLC), which separates the target 344-amino-acid peptide sequence from synthesis side-products, truncated sequences, and residual deletion peptides.
Complementary to HPLC, High-Resolution Mass Spectrometry (HRMS) is employed to verify the exact molecular mass and monoisotopic peptide fingerprint. Each product shipment includes a downloadable Certificate of Analysis (COA) detailing the specific lot number, purity percentage (consistently meeting or exceeding 98%), HPLC chromatograms, and MS spectra. Researchers can access these analytical documents directly through our centralized research library to maintain transparent, audit-ready laboratory records.
Endotoxin Testing and Bioactivity Assays for Cell Culture Rigor
In cell culture and organoid models, bacterial endotoxins—specifically lipopolysaccharides (LPS) derived from Gram-negative bacterial outer membranes—pose a critical threat to biological validity. High endotoxin levels induce non-specific inflammatory responses via Toll-Like Receptor 4 (TLR4) activation, triggering NF-κB transcription and confounding experimental observations related to TGF-β or myostatin signaling.
PX1 Research subjects all lot batches of Follistatin 344 to rigorous Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly controlled under standard research thresholds (< 0.1 EU/mg). This low-endotoxin standard ensures that observed cellular responses in vitro are driven solely by the native peptide mechanics rather than immunological interference caused by bacterial contaminants.
Comparative Analysis: Follistatin 344 vs. Related Pathway Modulators
When designing preclinical assays targeting muscle physiology, cellular differentiation, or organoid development, researchers often compare Follistatin 344 against other sequence variants and hypertrophic research peptides. Understanding the distinct properties of each compound allows for precise model selection and targeted assay development.
For example, while follistatin 344 serves as the full precursor peptide, the C-terminally truncated follistatin 315 variant exhibits reduced heparin-binding capabilities, leading to distinct systemic clearance rates in animal models. Alternatively, studies investigating independent hypertrophic pathways frequently evaluate igf-1 lr3, which signals through the Receptor Tyrosine Kinase (RTK) / MAPK cascade rather than suppressing Smad2/3 signaling. Researchers examining downstream repair pathways may also cross-reference tissue-remodeling data against peptides like bpc-157 to assess concurrent angiogenic and extracellular matrix responses in vitro.
Laboratory Handling, Reconstitution, and Storage Specifications
Follistatin 344 is supplied as a sterile, lyophilized cake or powder designed strictly for in vitro and laboratory research applications. To preserve peptide integrity and tertiary structure, proper storage and reconstitution protocols must be observed. Lyophilized vials should be stored at -20°C upon receipt, protected from light and moisture.
For reconstitution within a biosafety cabinet, researchers should utilize sterile Bacteriostatic Water or sterile phosphate-buffered saline (PBS, pH 7.4), depending on assay requirements. Gentle swirl reconstitution is recommended; vigorous agitation or vortexing must be avoided to prevent mechanical shear stress and peptide denaturation. Following reconstitution, aliquots should be prepared in single-use cryogenic vials and stored at -80°C to prevent degradation from repeated freeze-thaw cycles. Detailed reconstitution guidelines and concentration calculations are available in our peptide handling guide.
Supply Chain Reliability: Expedited Domestic Fulfillment
Experimental timelines rely heavily on punctual reagent delivery and steady inventory availability. PX1 Research eliminates supply chain bottlenecks by maintaining dual fulfillment hubs located in California and Arizona. Every order placed by laboratory personnel before cutoff times Monday through Friday qualifies for same-day dispatch.
Domestic warehousing minimizes thermal exposure risks associated with extended international transit times. Lyophilized peptides are packaged in temperature-monitored, insulated containers to preserve sequence stability throughout transit. Institutional clients managing high-throughput laboratories or grant-funded projects can establish streamlined procurement channels via our dedicated wholesale laboratory program.
Frequently Asked Questions
What is the primary role of Follistatin 344 in laboratory research?
Follistatin 344 is studied as an autocrine binding protein that antagonizes specific members of the TGF-β superfamily, primarily Activin A and Myostatin (GDF-8). Investigators utilize it in cell culture and animal models to evaluate cellular differentiation, myogenesis, and downstream Smad signaling inhibition.
Where is PX1 Research's Follistatin 344 synthesized?
PX1 Research Follistatin 344 is 100% synthesized in the United States within cGMP-compliant peptide synthesis facilities. This guarantees precise sequence verification, domestic quality control, and adherence to strict regulatory standards.
How is the purity and mass of Follistatin 344 verified?
Every batch undergoes rigorous third-party analysis at an ISO 17025-accredited laboratory. Analytical protocols include High-Performance Liquid Chromatography (HPLC) to confirm purity (≥ 98%) and High-Resolution Mass Spectrometry (HRMS) to confirm exact molecular identity.
What endotoxin controls are applied to this research compound?
Each lot is screened using Limulus Amebocyte Lysate (LAL) assaying to ensure endotoxin levels remain below strictly controlled laboratory thresholds (< 0.1 EU/mg), preventing non-specific inflammatory signaling in cell culture assays.
How should lyophilized Follistatin 344 be stored upon delivery?
Lyophilized Follistatin 344 should be stored at -20°C or -80°C in a dry environment protected from light. Under these conditions, the peptide maintains structural stability for extended periods.
What solvents should be used for laboratory reconstitution?
Depending on downstream application requirements, Follistatin 344 can be reconstituted using sterile Bacteriostatic Water or sterile phosphate-buffered saline (PBS, pH 7.4) under aseptic conditions within a laminar flow hood.
How does Follistatin 344 differ structurally from Follistatin 315?
Follistatin 344 is the full-length precursor polypeptide sequence. In vivo, carboxyl-terminal cleavage yields shorter isoforms like Follistatin 315, which exhibits different heparin-binding kinetics and cell-membrane association profiles.
Can institutional buyers request bulk quantities or custom lot testing?
Yes, PX1 Research provides dedicated procurement support for academic and commercial institutions. Bulk pricing, custom lot reservations, and specialized COA documentation can be coordinated through our wholesale department.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.